TABLE 1.
In vitro parasite growth inhibition by purified Ig of WT and KO mice immunized with P30P2MSP1-19 in different adjuvant formulations
| Adjuvant formulationa | Mouse strain in C57BL/6 background | Antibody response of KO mice compared to WT controlsb | In vitro parasite growth inhibition (%)c
|
|
|---|---|---|---|---|
| Homologous strain (FVO) | Heterologous strain (FUP) | |||
| ISA720 | WT | NA | 18.0/21.2 | 12.6/9.8 |
| IL-6 KO | + | 29.8/33.8 | ND | |
| CD80 KO | O | 30.2/35.6 | ND | |
| MF59 | WT | NA | 16.4/11.0 | ND |
| IL-6 KO | + | 27.4/20.2 | ND | |
| CD80 KO | O | 23.6/17.4 | ND | |
| QS21 | WT | NA | 0.0/9.2 | 7.6/1.4 |
| IL-6 KO | O | 6.8/7.2 | ND | |
| CD80 KO | O | 12.4/10.2 | ND | |
| CD86 KO | O | 0.0/0.8 | ND | |
| ICAM-1 KO | O | 11.8/5.6 | ND | |
| ISA720-QS21 | WT | NA | 0.0/3.8 | 5.0/11.4 |
| IL-6 KO | O | 9.6/9.8 | ND | |
| CD80 KO | O | 11.2/0.0 | ND | |
| CD86 KO | O | 0.0/0.0 | ND | |
| ISA720-MPL | WT | NA | 52.6/63.2 | 24.4/19.6 |
| IL-6 KO | O | 48.8/55.2 | 16.0/10.8 | |
| CD80 KO | O | 61.6/53.0 | 23.2/20.4 | |
| ICAM-1 KO | O | 60.8/57.6 | 17.8/21.2 | |
| ISA720-QS21-MPL | WT | NA | 62.2/61.2 | 29.6/20.2 |
| CD80 KO | O | 65.8/56.6 | 23.4/17.8 | |
| CD86 KO | O | 50.0/64.4 | 15.0/25.8 | |
| ICAM-1 KO | O | 53.2/60.0 | 21.0/12.6 | |
| MPL-SE | WT | NA | 68.6/66.0 | 28.8/19.8 |
| IL-6 KO | − | 61.4/58.4 | 21.4/23.0 | |
| CD80 KO | − | 47.8/45.4 | 10.6/5.8 | |
| CD86 KO | − | 57.8/59.0 | 25.8/14.8 | |
| ICAM-1 KO | O | 61.2/60.6 | 27.8/10.0 | |
| MPL-AF | WT | NA | 15.4/12.0 | 8.6/0.0 |
| IL-6 KO | O | 4.6/11.6 | ND | |
| CD80 KO | O | 17.0/0.0 | ND | |
| CD86 KO | − | 11.2/1.0 | ND | |
| ICAM-1 KO | O | 19.8/14.6 | ND | |
b
ELISA antibody titers to MSP1-19. Data were from references 11 and 13. NA, not applicable; +, titers higher than the titers in WT mice; O, titers not significantly different from those of WT mice; −, titers significantly lower than those of WT mice.
c
Percent parasite growth inhibition of test antibodies compared to preimmune serum antibodies from the same mouse group. Results of two independent assays are shown. ND, not done.